Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of obesity and type 2 diabetes mellitus (T2DM) by mimicking endogenous GLP-1 activity, increasing glucose-dependent insulin secretion and suppressing glucagon release
It plays a central role in energy production, regulating functions like metabolism, cell signaling, immune health, and DNA repair
Sources: November 6, 2025 White House fact sheet and manufacturer press releases To learn about GLP-1s, see our article, New Drugs for Weight Loss: What Plan Sponsors Need to Know. It appears that the TrumpRx prescription drug website, expected to be launched in early 2026, will link to the manufacturer DTC websites to allow purchase of the medications
Very fast delivery too
Valid concerns include lack of oversight, variability between batches, no recourse if something goes wrong, and potential legal implications
Immunomodulators include Thymosin Alpha-1 and KPV
![43.4% of your semaglutide weight loss is lean muscle., When [founders] and [executives] utilize [GLP-1 receptor agonists] for weight management, they often measure success strictly by the drop in](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3943944568013808410)
